Nemolizumab for Moderate-to-Severe Atopic Dermatitis
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Age
- 12 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Galderma R&D · Industry
This trial is looking for adolescents and adults with moderate-to-severe atopic dermatitis who are starting treatment with nemolizumab. Participants will be assessed by a doctor and will provide feedback about their experience after 6 months.
You may be able to join if
- I am aged 12 years or older
- I have moderate-to-severe atopic dermatitis
- I have signed the informed consent form or it has been signed for me
- My doctor has decided that I can start treatment with nemolizumab
You may not be able to join if
- I have a contraindication for using nemolizumab
- I have received treatment with a drug under clinical development in the past 3 months
- I have previously received nemolizumab
- I am unable to understand the consent form or complete study questionnaires
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Loading trial locations…